Evidence map›Paper›PMID 27581459›Full record

ArticleThe Journal of neuroscience : the official journal of the Society for Neuroscience2016

ERK1/2 Activation in Preexisting Oligodendrocytes of Adult Mice Drives New Myelin Synthesis and Enhanced CNS Function.

Marisa A Jeffries, Kelly Urbanek, Lester Torres, Stacy Gelhaus Wendell, Maria E Rubio, Sharyl L Fyffe-Maricich

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of neuroscience : the official journal of the Society for Neuroscience, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
75citing papers in PubMed, 1 pooled it
7.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

75 citing papers in PubMed, 1 synthesis or guideline pooled it, 113 citations in OpenAlex.

  1. Pooled it
  2. Beyond Histamine Blockade: Clemastine Fumarate as a Promoter of Myelin Regeneration, Inflammatory Regulation, and Neuroimmune Modulation in CNS Disorders.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2026
    Review
  3. Review
  4. Rethinking MS Therapeutics: From Disease Pathogenesis Mechanisms to AI-Driven Drug Discovery.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2026
    Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Development of Oligodendroglia and Myelin.Advances in neurobiology · 2025
    Review
  11. Article
  12. Article
  13. Dynamics of mature myelin.Nature neuroscience · 2024
    Review
  14. Article
  15. Article
  16. Neuronal activation of GCell reports · 2023
    Article
  17. Review
  18. Article
  19. Article
  20. Lysophosphatidic acid signaling via LPAJournal of neurochemistry · 2022
    Article

15 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Marisa A JeffriesCenter for Neuroscience.ORCID 0000-0002-2486-0457
Kelly UrbanekDepartment of Pediatrics, Division of Neurology, and.
Lester TorresDepartment of Otolaryngology, University of Pittsburgh, Pittsburgh, Pennsylvania 15224, and.
Stacy Gelhaus WendellDepartment of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, Pennsylvania 15261.ORCID 0000-0001-9083-6933
Maria E RubioCenter for Neuroscience, Department of Otolaryngology, University of Pittsburgh, Pittsburgh, Pennsylvania 15224, and.
Sharyl L Fyffe-MaricichCenter for Neuroscience, Department of Pediatrics, Division of Neurology, and sharyl.fyffemaricich@chp.edu.ORCID 0000-0001-5843-2023
University of Pittsburgh · USPediatrics and Genetics · USCenter for Neurosciences · US

Funding

Mechanisms of hypersensitivity to sound-induced cochlear damageR01DC013048 · NIDCD · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Maria-Eulalia Rubio-Valero · 2013 to 2026
$6.8M
The role of ERK1/2 MAP kinase signaling in CNS myelinationR01NS091084 · NINDS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI FYFFE-MARICICH, SHARYL LYNNE · 2015 to 2016
$664k
Request for transmission electron microscope for the University of PittsburghS10OD016236 · OD · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI WATKINS, SIMON C · 2013 to 2013
$459k
NIDCD NIH HHS R01 DC013048NIH HHS S10 OD016236NINDS NIH HHS R01 NS091084
6 · The paper itself

Abstract

unlabelledGrowing evidence shows that mechanisms controlling CNS plasticity extend beyond the synapse and that alterations in myelin can modify conduction velocity, leading to changes in neural circuitry. Although it is widely accepted that newly generated oligodendrocytes (OLs) produce myelin in the adult CNS, the contribution of preexisting OLs to functional myelin remodeling is not known. Here, we show that sustained activation of extracellular signal-regulated kinases 1 and 2 (ERK1/2) in preexisting OLs of adult mice is sufficient to drive increased myelin thickness, faster conduction speeds, and enhanced hippocampal-dependent emotional learning. Although preexisting OLs do not normally contribute to remyelination, we show that sustained activation of ERK1/2 renders them able to do so. These data suggest that strategies designed to push mature OLs to reinitiate myelination may be beneficial both for enhancing remyelination in demyelinating diseases and for increasing neural plasticity in the adult CNS. SIGNIFICANCE STATEMENT: Myelin is a crucial regulator of CNS plasticity, function, and repair. Although it is generally accepted that new myelin production in the adult CNS is initiated by newly generated oligodendrocytes (OLs), great interest remains in additionally driving mature preexisting OLs to make myelin. The ability to induce myelination by the larger population of preexisting OLs carries the potential for enhanced remyelination in demyelinating diseases and increased neural plasticity in the adult CNS. Here, we show that sustained activation of the extracellular signal-regulated kinases 1 and 2 (ERK1/2) signaling pathway is sufficient to drive mature OLs in the adult mouse CNS to reinitiate myelination, leading to new myelin wraps and functional changes.

Indexed as

Analysis of VarianceAnimalsCentral Nervous SystemConditioning, PsychologicalDemyelinating DiseasesDisease Models, AnimalEvoked Potentials, Auditory, Brain StemExploratory BehaviorFearGalactosylceramidesGreen Fluorescent ProteinsLysophospholipaseMAP Kinase Kinase 1MAP Kinase Signaling SystemMiceMice, Inbred C57BLenhanced green fluorescent proteinGalactosylceramidesGreen Fluorescent ProteinsLysophospholipaseMap2k1 protein, mouseMAP Kinase Kinase 1Mitogen-Activated Protein Kinase 3Myelin Proteolipid ProteinNerve Tissue ProteinsPlp1 protein, mouseRNA, MessengerERK MAP kinaseintracellular signalingmyelinmyelin plasticityoligodendrocyteremyelination

Identifiers

PMID27581459
PMCPMC5005725
OpenAlexW2515930820

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.